Alume Biosciences

AUM Biosciences, also known as Alume Biosciences, is leading the way in revolutionizing the drug development process in the field of oncology, aiming to provide innovative and cost-effective targeted medications for a wide range of cancers. AUM is dedicated to establishing a strong and cutting-edge pipeline of top-notch and groundbreaking small molecule therapies, utilizing the most advanced precision medicine and digital tools. Our fundamental focus on utilizing biomarkers, pioneering clinical trial methodologies, and harnessing intelligent data sets us apart from other entities in the drug development sector. This approach empowers us to identify inventive early-stage compounds that can be swiftly advanced into successful treatments. Caelum Biosciences, Inc., commonly referred to as Caelum, is a biotechnology company in the clinical development stage, concentrating on developing therapies for rare and life-threatening illnesses. The primary asset of Caelum, CAEL-101 (mAb 11-1F4), is a new antibody that was licensed from Columbia University in January 2017 for treating amyloid light chain (AL) amyloidosis, a rare systemic disease with the potential of causing organ failure and mortality. The company has presented Phase 1a/1b data at various prestigious medical conferences, including the American Society of Hematology’s 59th Annual Meeting in December 2017, the 16th International Symposium on Amyloidosis in March 2018, as well as the American Society of Echocardiography 29th Annual Scientific Sessions in June 2018.